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Abstract  
The EQ-5D-3L version has long been the preferred measure of health-related utility estimates for the 
National Institute for Health and Care Excellence (NICE). Over time, concerns about the EQ-5D-3L 
have been raised, focusing on its sensitivity to changes in health state, ceiling effects, and the 
uneven distribution of values across the states. In response, the EuroQol group developed an 
alternative five-level version, the EQ-5D-5L, and in 2013 NICE recommended the 5L version for use in 
reference case analyses. Subsequently, the new version of the instrument has been widely adopted 
in clinical research and for economic evaluation, typically at the expense of the EQ-5D-3L version. 
Yet this begs the question and assumes the 5L version is simply a minor change to the 3L version that 
can be adopted without consideration of its own merits. It is right to ask, however, whether it is 
more than just a minor variant of the 3L. The 3L version has been tested and validated in a wide 
range of patient groups – the same cannot yet be said for the 5L version. Additionally, the 3L version 
was adopted at a time when reliable alternative measures of outcome were scarce – the same 
cannot be said now.  Here I argue that analysts and reimbursement authorities such as NICE should 
exercise caution and consider the whole range of alternative tools before adopting the 5L version as 
the reference case.  
  
1. The EQ-5D-5L 
The Euro-Qol group introduced the EQ-5D-5L descriptive system in 2009 [1], with the 1st publication 
describing the tool appearing in 2011 [2]. This revised version of the EQ-5D instrument introduced five 
response-levels, alongside changes to the wording used to describe responses in the mobility domain. 
The five-level version of the EQ-5D descriptive system was developed in response to perceived failings 
of the three response-level EQ-5D-3L, notably in its sensitivity to changes in health [3], but also ceiling 
effects [2] and an ‘uneven’ distribution of responses as measured by the valuation tariff [4].  
The first UK valuation study of the 5L descriptive system was formally available in 2017 [4]. As Brazier, 
Bryan and Briggs recently summarize [5], the 5L version of the instrument has been found to reduce 
ceiling effects and exhibits a more even distribution of responses. Hernandez et al [6] have shown that 
as a consequence of the changes to the tool and the new valuation system, utility scores derived using 
the 5L version are compressed towards the full health end of the measurement scale, suggesting that 
while the 5L version describes more distinct health states, the values placed on them are potentially 
less sensitive for detecting clinically meaningful changes in health utility. Given the existing 3L and 5L 
valuation tariffs, cost-effectiveness analyses using different versions of the tool are likely to lead to 
different results and possibly different decisions on the cost-effectiveness of interventions.   
2. Minor changes, major impact? 
The response of the National Institute for Health and Care Excellence (NICE), the UK body responsible 
for health technology appraisal and reimbursement decisions, to the challenges above has been to 
commission further research into the impacts of changing from the 3L version of the instrument to 
the 5L version. This is sensible for two reasons that are widely acknowledged, and a third that is less 
so. First, a change from 3L to the 5L, and the consequent change in tariffs, will lead to questions being 
raised over the historical decisions taken by NICE – would an intervention that was cost-effective as 
assessed under the 3L be cost-effective if the 5L had been used? NICE are undertaking work to 
consider the implications of this [7]. 
The second reason relates to the choice of comparators in evaluations. If the 3L and 5L tariffs give 
different answers to empirical questions, is it appropriate to compare across them when judging 
whether interventions are cost-effective? Technology appraisals frequently rely on decision models 
that draw on a wide range of sources. Are comparisons within a technology appraisal valid if the 
benefits of an existing intervention have been valued from the 3L version, while benefits of a new 
intervention are measured using the 5L? One approach that would allow this would be to map 
between tools (assuming the availability of patient level data), and this is being considered as part of 
the review of the evidence commissioned by NICE [7]. But in many cases, it will not be possible to 
map, and guidance will need to be developed to inform analysts when faced with this challenge.   
The third reason to be cautious about adoption of the 5L – and one that is not knowingly being 
explored by NICE, is that the two instruments, are, even if only subtly, different. And just as we would 
not expect the EQ-5D-3L and the SF-6D to lead to the same utility scores and decisions, what 
justification would there be to believe, a priori, that the 3L and 5L versions of the EQ-5D would give 
rise to the same weights and same decisions?  
While no one suggests that the results are expected to be identical, there appears to have been an 
assumption, as evidenced by the NICE position statement, that the EQ-5D-5L was the natural successor 
to the 3L [7]. In fact, the 2013 NICE guidance on technology appraisal methods permits the use of the 
5L version in reference case analyses [8] in the absence of a valuation set or a body of evidence on the 
validity of the tool. Given this, and the timing of the position statement from NICE, it seems reasonable 
to believe that the EQ-5D-5L was the anointed reference-case successor, and that is it perhaps an 
unexpected set of results arising from the valuation study that have led to delay in coronation.   
3. Validity 
Is the 5L version of the EQ-5D simply a minor variation from the 3L version, or is it more than that? 
This question is especially pertinent when we consider the validity of the tools we use to measure 
outcomes in a study – the validity of the measurement tool is crucial in assessing the validity of the 
conclusions drawn based on it. The 3L version has been tested for suitability across a wide range of 
populations, including diabetes [9], dementia [10], deafness [11] and depression [12] (and that’s just 
a sample from the Ds). The 5L version has not yet been subject to this extensive level of assessment. 
And while some studies have compared the measurement properties of the 5L version to the 3L 
version [13], if the 3L version is already not considered adequate, its use as a comparator in validity 
assessment seems oblique.  
The 3L version has also been found wanting in populations, including for many mental health 
conditions [14, 15], for children [16], and for people at the end of life [17]. In response, alternative 
tools  such as the Recovering Quality of Life instrument [18], CHU-9D [19] and the ICECAP-SCM [20] 
have been developed for use in these populations. If the EQ-5D-3L was considered not valid in these 
groups, what can we say about the EQ-5D-5L? Additional testing will be required, and it cannot 
necessarily be assumed that the 5L will either overcome or have the same measurement problems 
(though our prior beliefs may vary according to why the EQ-5D-3L was not considered suitable in any 
given group).   
We can only answer the above questions by subjecting the 5L version to a period of assessment and 
validation work. Many researchers in recent years have included the 5L tool as the outcome measure 
for economic evaluation without this validation work having occurred – the author included [21] – on 
the assumption that the two instruments were effectively interchangeable. With hindsight, this 
assumption looks increasingly inappropriate. Ongoing studies should examine how the EQ-5D-5L 
performs within the study populations and report this, but whether the economic evaluation results 
are reliable will need to be assessed on a case-by-case basis.  
It seems likely that adopting the 5L version in the absence of the required validation work could lead 
to the same outcome as with the 3L – an instrument adopted as a de facto gold standard in the 
absence of a sufficiently robust evidence base. In 2004 NICE determined that ‘the most appropriate 
choice in the UK appears to be the EQ-5D’ [22], with a firmer recommendation in 2008 [23]. But 14 
years on from that first guidance there are, in 2018, a range of generic preference-based instruments 
measuring and health and beyond from which to choose – should the EQ-5D-5L be privileged over this 
set of existing instruments owing to its parentage, or should it be treated as merely the latest addition 
to this panoply?  
4. Proceed with caution 
Recognising that the 3L and 5L versions are different, even if they are closely related, leads us to an 
unavoidable question – is it reasonable to simply adopt the 5L version of the tool in place of the 3L 
version? NICE are considering the technical implications of doing so, in terms of the outcomes of 
decision making, and this is important, but it does assume that the replacement for the 3L should be 
the 5L. Yet it is reasonable to ask – if the decision is made to change the reference case quality of life 
instrument from the EQ-5D-3L, is the 5L version the best choice? There are a wide range of preference-
based measures of quality of life tool available to the health economist, and an expanding range of 
alternative outcome measures based on concepts such as capabilities [24] or subjective well-being 
[25]. Many of these alternatives, notably the SF-6D, have a robust body of research spanning many 
years and supporting their use in a wide variety of patient groups [26-31].  This is something the EQ-
5D-5L currently lacks and will only gain through time. Consideration should at least be given to 
alternatives before adopting the EQ-5D-5L.   
Perhaps it is useful to finish with a thought experiment – if the EQ-5D-3L had never existed, would 
anyone develop the 5L version? Would it solve a problem not solved by a competing tool? In a 
competitive marketplace, would adoption of the 5L tool be justified, given its already contested 
descriptive system and valuation study [5]? Or would a different instrument be preferred? The health 
economics community has been bitten before by adopting a tool it did not fully understand as the 
reference case for evaluation – perhaps we should be a little bit shy before adopting its successor.   
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